Table 3.
Prevalence of atopic conditions in previously published studies of brain tumors and two US cross-sectional studies
| Study | Population (Country) | Prevalence | |||
|---|---|---|---|---|---|
| Allergy | Asthma | Eczema | Any of the Three Conditions | ||
| Brenner et al. (4) | Hospital-based controls (USA) | 38–41% | |||
| Cicuttini et al. (5) | Population-based controls (Australia) | 11% | 8% | ||
| Hochberg et al. (6) | Friend controls | 34% | |||
| Schlehofer et al., 1999 (8) | Population-based controls (International: 6 countries)* | 31% | 7% | 9% | |
| Schlehofer et al., 1992 (9) | Population-based controls (Germany) | 38% | |||
| Schoemaker et al. (10) | Population-based controls (UK) | 23% | 13% | 13% | 62% |
| Schwartzbaum et al. (11) | Twin’s cohorts (Sweden) | 17–31% | 3% | ||
| Wiemels et al. (12) | Population-based controls (USA) | 85% | |||
| Wigertz et al. (13) | Population-based controls (International: 5 countries)† | 46% | 10% | 18% | |
| Arbes et al. (15) | NHANES III‡ (USA) | 54% | |||
| Kilmer et al. (16) | BRFSS§ (USA) | 4.5% | |||
*
Countries included are Australia, Canada, France, Germany, Sweden, and USA.
†
Countries included are Denmark, Finland, Norway, Sweden, and UK.
‡
National Health and Nutrition Examination Survey III – population-based cross-sectional study.
§
Behavioral Risk Factor Surveillance System – population-based cross-sectional study.